Aggressive antipyretics in central nervous system malaria: Study protocol of a randomized-controlled trial assessing antipyretic efficacy and parasite clearance effects (Malaria FEVER study)

Malaria remains a major public health challenge in Africa where annually, ~250,000 children with malaria experience a neurologic injury with subsequent neuro-disability. Evidence indicates that a higher temperature during the acute illness is a risk factor for post-infectious neurologic sequelae. As...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 17; no. 10; p. e0268414
Main Authors Chilombe, Moses B, McDermott, Michael P, Seydel, Karl B, Mathews, Manoj, Mwenechanya, Musaku, Birbeck, Gretchen L
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 07.10.2022
Public Library of Science (PLoS)
Subjects
Acetaminophen
Acetaminophen - therapeutic use
Analgesics
Animals
Antipyretics
Antipyretics - therapeutic use
Biology and Life Sciences
Brain injury
Causes of
Central Nervous System
Central nervous system diseases
Child
Children
Clinical trials
Coma
Complications and side effects
Convulsions & seizures
Drug therapy
Effectiveness
Epilepsy
Evaluation
Fever
Fever - drug therapy
Fever - prevention & control
Head injuries
Health risks
Health services
Histidine
Humans
Hyperthermia
Ibuprofen
Ibuprofen - therapeutic use
Informed consent
Malaria
Malaria, Falciparum - complications
Malaria, Falciparum - drug therapy
Maximum temperatures
Medicine and Health Sciences
Neurological complications
Neuroprotection
Neuroprotective Agents - therapeutic use
Nonsteroidal anti-inflammatory drugs
Parasites
Pediatrics
People and Places
Peripheral blood
Proteins
Public health
Randomization
Randomized Controlled Trials as Topic
Reduction
Risk analysis
Risk factors
Seizures
Seizures - drug therapy
Study Protocol
Temperature effects
Testing
Therapy
Traumatic brain injury
Treatment Outcome
Vector-borne diseases
Zambia
Zambia
United States
Malawi
United States > US
Online AccessGet full text

Cover

Abstract Malaria remains a major public health challenge in Africa where annually, ~250,000 children with malaria experience a neurologic injury with subsequent neuro-disability. Evidence indicates that a higher temperature during the acute illness is a risk factor for post-infectious neurologic sequelae. As such, aggressive antipyretic therapy may be warranted among children with complicated malaria at substantial risk of brain injury. Previous clinical trials conducted primarily in children with uncomplicated malaria and using only a single antipyretic medication have shown limited benefits in terms of fever reduction; however, no studies to date have examined malaria fever management using dual therapies. In this clinical trial of aggressive antipyretic therapy, children hospitalized with central nervous system (CNS) malaria will be randomized to usual care (acetaminophen every 6 hours for a temperature ≥ 38.5°C) vs. prophylactic acetaminophen and ibuprofen every 6 hours for 72 hours. In this double-blinded, placebo controlled, two-armed clinical trial, we will enroll 284 participants from three settings at Queen Elizabeth Central Hospital in Blantyre, Malawi; at the University Teaching Hospitals Children's Hospital in Lusaka, Zambia and at Chipata Central Hospital, Chipata, Zambia. Parents or guardians must provide written informed consent. Eligible participants are 2-11 years with evidence of P. falciparum malaria infection by peripheral blood smear or rapid diagnostic test with CNS symptoms associated with malaria. Eligible children will receive treatment allocation randomization either to standard of care for fever management or to prophylactic, scheduled treatment every 6 hours for 72 hours with dual antipyretic therapies using acetaminophen and ibuprofen. Assignment to treatment groups will be with 1:1 allocation using blocked randomization. The primary outcome will be maximum temperature in the 72 hours after enrolment. Secondary outcomes include parasite clearance as determined by quantitative Histidine Rich Protein II and seizures through 72 hours after enrolment. This clinical trial seeks to challenge the practice paradigm of limited fever treatment based upon hyperpyrexia by evaluating the fever-reduction efficacy of more aggressive antipyretic using two antipyretics and prophylactic administration and will elucidate the impact of antipyretics on parasite clearance and acute symptomatic seizures. If aggressive antipyretic therapy is shown to safely reduce the maximum temperature, a clinical trial evaluating the neuroprotective effects of temperature reduction in CNS malaria is warranted.
AbstractList Background Malaria remains a major public health challenge in Africa where annually, ~250,000 children with malaria experience a neurologic injury with subsequent neuro-disability. Evidence indicates that a higher temperature during the acute illness is a risk factor for post-infectious neurologic sequelae. As such, aggressive antipyretic therapy may be warranted among children with complicated malaria at substantial risk of brain injury. Previous clinical trials conducted primarily in children with uncomplicated malaria and using only a single antipyretic medication have shown limited benefits in terms of fever reduction; however, no studies to date have examined malaria fever management using dual therapies. In this clinical trial of aggressive antipyretic therapy, children hospitalized with central nervous system (CNS) malaria will be randomized to usual care (acetaminophen every 6 hours for a temperature [greater than or equal to] 38.5°C) vs. prophylactic acetaminophen and ibuprofen every 6 hours for 72 hours. Methods In this double-blinded, placebo controlled, two-armed clinical trial, we will enroll 284 participants from three settings at Queen Elizabeth Central Hospital in Blantyre, Malawi; at the University Teaching Hospitals Children's Hospital in Lusaka, Zambia and at Chipata Central Hospital, Chipata, Zambia. Parents or guardians must provide written informed consent. Eligible participants are 2-11 years with evidence of P. falciparum malaria infection by peripheral blood smear or rapid diagnostic test with CNS symptoms associated with malaria. Eligible children will receive treatment allocation randomization either to standard of care for fever management or to prophylactic, scheduled treatment every 6 hours for 72 hours with dual antipyretic therapies using acetaminophen and ibuprofen. Assignment to treatment groups will be with 1:1 allocation using blocked randomization. The primary outcome will be maximum temperature in the 72 hours after enrolment. Secondary outcomes include parasite clearance as determined by quantitative Histidine Rich Protein II and seizures through 72 hours after enrolment. Discussion This clinical trial seeks to challenge the practice paradigm of limited fever treatment based upon hyperpyrexia by evaluating the fever-reduction efficacy of more aggressive antipyretic using two antipyretics and prophylactic administration and will elucidate the impact of antipyretics on parasite clearance and acute symptomatic seizures. If aggressive antipyretic therapy is shown to safely reduce the maximum temperature, a clinical trial evaluating the neuroprotective effects of temperature reduction in CNS malaria is warranted.
Malaria remains a major public health challenge in Africa where annually, ~250,000 children with malaria experience a neurologic injury with subsequent neuro-disability. Evidence indicates that a higher temperature during the acute illness is a risk factor for post-infectious neurologic sequelae. As such, aggressive antipyretic therapy may be warranted among children with complicated malaria at substantial risk of brain injury. Previous clinical trials conducted primarily in children with uncomplicated malaria and using only a single antipyretic medication have shown limited benefits in terms of fever reduction; however, no studies to date have examined malaria fever management using dual therapies. In this clinical trial of aggressive antipyretic therapy, children hospitalized with central nervous system (CNS) malaria will be randomized to usual care (acetaminophen every 6 hours for a temperature [greater than or equal to] 38.5°C) vs. prophylactic acetaminophen and ibuprofen every 6 hours for 72 hours. In this double-blinded, placebo controlled, two-armed clinical trial, we will enroll 284 participants from three settings at Queen Elizabeth Central Hospital in Blantyre, Malawi; at the University Teaching Hospitals Children's Hospital in Lusaka, Zambia and at Chipata Central Hospital, Chipata, Zambia. Parents or guardians must provide written informed consent. Eligible participants are 2-11 years with evidence of P. falciparum malaria infection by peripheral blood smear or rapid diagnostic test with CNS symptoms associated with malaria. Eligible children will receive treatment allocation randomization either to standard of care for fever management or to prophylactic, scheduled treatment every 6 hours for 72 hours with dual antipyretic therapies using acetaminophen and ibuprofen. Assignment to treatment groups will be with 1:1 allocation using blocked randomization. The primary outcome will be maximum temperature in the 72 hours after enrolment. Secondary outcomes include parasite clearance as determined by quantitative Histidine Rich Protein II and seizures through 72 hours after enrolment. This clinical trial seeks to challenge the practice paradigm of limited fever treatment based upon hyperpyrexia by evaluating the fever-reduction efficacy of more aggressive antipyretic using two antipyretics and prophylactic administration and will elucidate the impact of antipyretics on parasite clearance and acute symptomatic seizures. If aggressive antipyretic therapy is shown to safely reduce the maximum temperature, a clinical trial evaluating the neuroprotective effects of temperature reduction in CNS malaria is warranted.
Background Malaria remains a major public health challenge in Africa where annually, ~250,000 children with malaria experience a neurologic injury with subsequent neuro-disability. Evidence indicates that a higher temperature during the acute illness is a risk factor for post-infectious neurologic sequelae. As such, aggressive antipyretic therapy may be warranted among children with complicated malaria at substantial risk of brain injury. Previous clinical trials conducted primarily in children with uncomplicated malaria and using only a single antipyretic medication have shown limited benefits in terms of fever reduction; however, no studies to date have examined malaria fever management using dual therapies. In this clinical trial of aggressive antipyretic therapy, children hospitalized with central nervous system (CNS) malaria will be randomized to usual care (acetaminophen every 6 hours for a temperature ≥ 38.5°C) vs. prophylactic acetaminophen and ibuprofen every 6 hours for 72 hours. Methods In this double-blinded, placebo controlled, two-armed clinical trial, we will enroll 284 participants from three settings at Queen Elizabeth Central Hospital in Blantyre, Malawi; at the University Teaching Hospitals Children’s Hospital in Lusaka, Zambia and at Chipata Central Hospital, Chipata, Zambia. Parents or guardians must provide written informed consent. Eligible participants are 2–11 years with evidence of P . falciparum malaria infection by peripheral blood smear or rapid diagnostic test with CNS symptoms associated with malaria. Eligible children will receive treatment allocation randomization either to standard of care for fever management or to prophylactic, scheduled treatment every 6 hours for 72 hours with dual antipyretic therapies using acetaminophen and ibuprofen. Assignment to treatment groups will be with 1:1 allocation using blocked randomization. The primary outcome will be maximum temperature in the 72 hours after enrolment. Secondary outcomes include parasite clearance as determined by quantitative Histidine Rich Protein II and seizures through 72 hours after enrolment. Discussion This clinical trial seeks to challenge the practice paradigm of limited fever treatment based upon hyperpyrexia by evaluating the fever-reduction efficacy of more aggressive antipyretic using two antipyretics and prophylactic administration and will elucidate the impact of antipyretics on parasite clearance and acute symptomatic seizures. If aggressive antipyretic therapy is shown to safely reduce the maximum temperature, a clinical trial evaluating the neuroprotective effects of temperature reduction in CNS malaria is warranted.
Background Malaria remains a major public health challenge in Africa where annually, ~250,000 children with malaria experience a neurologic injury with subsequent neuro-disability. Evidence indicates that a higher temperature during the acute illness is a risk factor for post-infectious neurologic sequelae. As such, aggressive antipyretic therapy may be warranted among children with complicated malaria at substantial risk of brain injury. Previous clinical trials conducted primarily in children with uncomplicated malaria and using only a single antipyretic medication have shown limited benefits in terms of fever reduction; however, no studies to date have examined malaria fever management using dual therapies. In this clinical trial of aggressive antipyretic therapy, children hospitalized with central nervous system (CNS) malaria will be randomized to usual care (acetaminophen every 6 hours for a temperature ≥ 38.5°C) vs. prophylactic acetaminophen and ibuprofen every 6 hours for 72 hours. Methods In this double-blinded, placebo controlled, two-armed clinical trial, we will enroll 284 participants from three settings at Queen Elizabeth Central Hospital in Blantyre, Malawi; at the University Teaching Hospitals Children’s Hospital in Lusaka, Zambia and at Chipata Central Hospital, Chipata, Zambia. Parents or guardians must provide written informed consent. Eligible participants are 2–11 years with evidence of P . falciparum malaria infection by peripheral blood smear or rapid diagnostic test with CNS symptoms associated with malaria. Eligible children will receive treatment allocation randomization either to standard of care for fever management or to prophylactic, scheduled treatment every 6 hours for 72 hours with dual antipyretic therapies using acetaminophen and ibuprofen. Assignment to treatment groups will be with 1:1 allocation using blocked randomization. The primary outcome will be maximum temperature in the 72 hours after enrolment. Secondary outcomes include parasite clearance as determined by quantitative Histidine Rich Protein II and seizures through 72 hours after enrolment. Discussion This clinical trial seeks to challenge the practice paradigm of limited fever treatment based upon hyperpyrexia by evaluating the fever-reduction efficacy of more aggressive antipyretic using two antipyretics and prophylactic administration and will elucidate the impact of antipyretics on parasite clearance and acute symptomatic seizures. If aggressive antipyretic therapy is shown to safely reduce the maximum temperature, a clinical trial evaluating the neuroprotective effects of temperature reduction in CNS malaria is warranted.
Malaria remains a major public health challenge in Africa where annually, ~250,000 children with malaria experience a neurologic injury with subsequent neuro-disability. Evidence indicates that a higher temperature during the acute illness is a risk factor for post-infectious neurologic sequelae. As such, aggressive antipyretic therapy may be warranted among children with complicated malaria at substantial risk of brain injury. Previous clinical trials conducted primarily in children with uncomplicated malaria and using only a single antipyretic medication have shown limited benefits in terms of fever reduction; however, no studies to date have examined malaria fever management using dual therapies. In this clinical trial of aggressive antipyretic therapy, children hospitalized with central nervous system (CNS) malaria will be randomized to usual care (acetaminophen every 6 hours for a temperature ≥ 38.5°C) vs. prophylactic acetaminophen and ibuprofen every 6 hours for 72 hours.BACKGROUNDMalaria remains a major public health challenge in Africa where annually, ~250,000 children with malaria experience a neurologic injury with subsequent neuro-disability. Evidence indicates that a higher temperature during the acute illness is a risk factor for post-infectious neurologic sequelae. As such, aggressive antipyretic therapy may be warranted among children with complicated malaria at substantial risk of brain injury. Previous clinical trials conducted primarily in children with uncomplicated malaria and using only a single antipyretic medication have shown limited benefits in terms of fever reduction; however, no studies to date have examined malaria fever management using dual therapies. In this clinical trial of aggressive antipyretic therapy, children hospitalized with central nervous system (CNS) malaria will be randomized to usual care (acetaminophen every 6 hours for a temperature ≥ 38.5°C) vs. prophylactic acetaminophen and ibuprofen every 6 hours for 72 hours.In this double-blinded, placebo controlled, two-armed clinical trial, we will enroll 284 participants from three settings at Queen Elizabeth Central Hospital in Blantyre, Malawi; at the University Teaching Hospitals Children's Hospital in Lusaka, Zambia and at Chipata Central Hospital, Chipata, Zambia. Parents or guardians must provide written informed consent. Eligible participants are 2-11 years with evidence of P. falciparum malaria infection by peripheral blood smear or rapid diagnostic test with CNS symptoms associated with malaria. Eligible children will receive treatment allocation randomization either to standard of care for fever management or to prophylactic, scheduled treatment every 6 hours for 72 hours with dual antipyretic therapies using acetaminophen and ibuprofen. Assignment to treatment groups will be with 1:1 allocation using blocked randomization. The primary outcome will be maximum temperature in the 72 hours after enrolment. Secondary outcomes include parasite clearance as determined by quantitative Histidine Rich Protein II and seizures through 72 hours after enrolment.METHODSIn this double-blinded, placebo controlled, two-armed clinical trial, we will enroll 284 participants from three settings at Queen Elizabeth Central Hospital in Blantyre, Malawi; at the University Teaching Hospitals Children's Hospital in Lusaka, Zambia and at Chipata Central Hospital, Chipata, Zambia. Parents or guardians must provide written informed consent. Eligible participants are 2-11 years with evidence of P. falciparum malaria infection by peripheral blood smear or rapid diagnostic test with CNS symptoms associated with malaria. Eligible children will receive treatment allocation randomization either to standard of care for fever management or to prophylactic, scheduled treatment every 6 hours for 72 hours with dual antipyretic therapies using acetaminophen and ibuprofen. Assignment to treatment groups will be with 1:1 allocation using blocked randomization. The primary outcome will be maximum temperature in the 72 hours after enrolment. Secondary outcomes include parasite clearance as determined by quantitative Histidine Rich Protein II and seizures through 72 hours after enrolment.This clinical trial seeks to challenge the practice paradigm of limited fever treatment based upon hyperpyrexia by evaluating the fever-reduction efficacy of more aggressive antipyretic using two antipyretics and prophylactic administration and will elucidate the impact of antipyretics on parasite clearance and acute symptomatic seizures. If aggressive antipyretic therapy is shown to safely reduce the maximum temperature, a clinical trial evaluating the neuroprotective effects of temperature reduction in CNS malaria is warranted.DISCUSSIONThis clinical trial seeks to challenge the practice paradigm of limited fever treatment based upon hyperpyrexia by evaluating the fever-reduction efficacy of more aggressive antipyretic using two antipyretics and prophylactic administration and will elucidate the impact of antipyretics on parasite clearance and acute symptomatic seizures. If aggressive antipyretic therapy is shown to safely reduce the maximum temperature, a clinical trial evaluating the neuroprotective effects of temperature reduction in CNS malaria is warranted.
BackgroundMalaria remains a major public health challenge in Africa where annually, ~250,000 children with malaria experience a neurologic injury with subsequent neuro-disability. Evidence indicates that a higher temperature during the acute illness is a risk factor for post-infectious neurologic sequelae. As such, aggressive antipyretic therapy may be warranted among children with complicated malaria at substantial risk of brain injury. Previous clinical trials conducted primarily in children with uncomplicated malaria and using only a single antipyretic medication have shown limited benefits in terms of fever reduction; however, no studies to date have examined malaria fever management using dual therapies. In this clinical trial of aggressive antipyretic therapy, children hospitalized with central nervous system (CNS) malaria will be randomized to usual care (acetaminophen every 6 hours for a temperature ≥ 38.5°C) vs. prophylactic acetaminophen and ibuprofen every 6 hours for 72 hours.MethodsIn this double-blinded, placebo controlled, two-armed clinical trial, we will enroll 284 participants from three settings at Queen Elizabeth Central Hospital in Blantyre, Malawi; at the University Teaching Hospitals Children's Hospital in Lusaka, Zambia and at Chipata Central Hospital, Chipata, Zambia. Parents or guardians must provide written informed consent. Eligible participants are 2-11 years with evidence of P. falciparum malaria infection by peripheral blood smear or rapid diagnostic test with CNS symptoms associated with malaria. Eligible children will receive treatment allocation randomization either to standard of care for fever management or to prophylactic, scheduled treatment every 6 hours for 72 hours with dual antipyretic therapies using acetaminophen and ibuprofen. Assignment to treatment groups will be with 1:1 allocation using blocked randomization. The primary outcome will be maximum temperature in the 72 hours after enrolment. Secondary outcomes include parasite clearance as determined by quantitative Histidine Rich Protein II and seizures through 72 hours after enrolment.DiscussionThis clinical trial seeks to challenge the practice paradigm of limited fever treatment based upon hyperpyrexia by evaluating the fever-reduction efficacy of more aggressive antipyretic using two antipyretics and prophylactic administration and will elucidate the impact of antipyretics on parasite clearance and acute symptomatic seizures. If aggressive antipyretic therapy is shown to safely reduce the maximum temperature, a clinical trial evaluating the neuroprotective effects of temperature reduction in CNS malaria is warranted.
Malaria remains a major public health challenge in Africa where annually, ~250,000 children with malaria experience a neurologic injury with subsequent neuro-disability. Evidence indicates that a higher temperature during the acute illness is a risk factor for post-infectious neurologic sequelae. As such, aggressive antipyretic therapy may be warranted among children with complicated malaria at substantial risk of brain injury. Previous clinical trials conducted primarily in children with uncomplicated malaria and using only a single antipyretic medication have shown limited benefits in terms of fever reduction; however, no studies to date have examined malaria fever management using dual therapies. In this clinical trial of aggressive antipyretic therapy, children hospitalized with central nervous system (CNS) malaria will be randomized to usual care (acetaminophen every 6 hours for a temperature ≥ 38.5°C) vs. prophylactic acetaminophen and ibuprofen every 6 hours for 72 hours. In this double-blinded, placebo controlled, two-armed clinical trial, we will enroll 284 participants from three settings at Queen Elizabeth Central Hospital in Blantyre, Malawi; at the University Teaching Hospitals Children's Hospital in Lusaka, Zambia and at Chipata Central Hospital, Chipata, Zambia. Parents or guardians must provide written informed consent. Eligible participants are 2-11 years with evidence of P. falciparum malaria infection by peripheral blood smear or rapid diagnostic test with CNS symptoms associated with malaria. Eligible children will receive treatment allocation randomization either to standard of care for fever management or to prophylactic, scheduled treatment every 6 hours for 72 hours with dual antipyretic therapies using acetaminophen and ibuprofen. Assignment to treatment groups will be with 1:1 allocation using blocked randomization. The primary outcome will be maximum temperature in the 72 hours after enrolment. Secondary outcomes include parasite clearance as determined by quantitative Histidine Rich Protein II and seizures through 72 hours after enrolment. This clinical trial seeks to challenge the practice paradigm of limited fever treatment based upon hyperpyrexia by evaluating the fever-reduction efficacy of more aggressive antipyretic using two antipyretics and prophylactic administration and will elucidate the impact of antipyretics on parasite clearance and acute symptomatic seizures. If aggressive antipyretic therapy is shown to safely reduce the maximum temperature, a clinical trial evaluating the neuroprotective effects of temperature reduction in CNS malaria is warranted.
Background Malaria remains a major public health challenge in Africa where annually, ~250,000 children with malaria experience a neurologic injury with subsequent neuro-disability. Evidence indicates that a higher temperature during the acute illness is a risk factor for post-infectious neurologic sequelae. As such, aggressive antipyretic therapy may be warranted among children with complicated malaria at substantial risk of brain injury. Previous clinical trials conducted primarily in children with uncomplicated malaria and using only a single antipyretic medication have shown limited benefits in terms of fever reduction; however, no studies to date have examined malaria fever management using dual therapies. In this clinical trial of aggressive antipyretic therapy, children hospitalized with central nervous system (CNS) malaria will be randomized to usual care (acetaminophen every 6 hours for a temperature ≥ 38.5°C) vs. prophylactic acetaminophen and ibuprofen every 6 hours for 72 hours. Methods In this double-blinded, placebo controlled, two-armed clinical trial, we will enroll 284 participants from three settings at Queen Elizabeth Central Hospital in Blantyre, Malawi; at the University Teaching Hospitals Children’s Hospital in Lusaka, Zambia and at Chipata Central Hospital, Chipata, Zambia. Parents or guardians must provide written informed consent. Eligible participants are 2–11 years with evidence of P. falciparum malaria infection by peripheral blood smear or rapid diagnostic test with CNS symptoms associated with malaria. Eligible children will receive treatment allocation randomization either to standard of care for fever management or to prophylactic, scheduled treatment every 6 hours for 72 hours with dual antipyretic therapies using acetaminophen and ibuprofen. Assignment to treatment groups will be with 1:1 allocation using blocked randomization. The primary outcome will be maximum temperature in the 72 hours after enrolment. Secondary outcomes include parasite clearance as determined by quantitative Histidine Rich Protein II and seizures through 72 hours after enrolment. Discussion This clinical trial seeks to challenge the practice paradigm of limited fever treatment based upon hyperpyrexia by evaluating the fever-reduction efficacy of more aggressive antipyretic using two antipyretics and prophylactic administration and will elucidate the impact of antipyretics on parasite clearance and acute symptomatic seizures. If aggressive antipyretic therapy is shown to safely reduce the maximum temperature, a clinical trial evaluating the neuroprotective effects of temperature reduction in CNS malaria is warranted.
Audience Academic
Author Seydel, Karl B
Mwenechanya, Musaku
Chilombe, Moses B
McDermott, Michael P
Mathews, Manoj
Birbeck, Gretchen L
AuthorAffiliation 3 Department of Osteopathic Medical Specialties, College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan, United States of America
5 University of Zambia School of Medicine, Lusaka, Zambia
6 Department of Neurology, University of Rochester, Rochester, New York, United States of America
2 Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, United States of America
Bach Mai Hospital, VIET NAM
4 University Teaching Hospitals Children’s Hospital, Lusaka, Zambia
1 Blantyre Malaria Project, Queen Elizabeth Central Hospital, Blantyre, Malawi
AuthorAffiliation_xml – name: 5 University of Zambia School of Medicine, Lusaka, Zambia
– name: 2 Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, United States of America
– name: 4 University Teaching Hospitals Children’s Hospital, Lusaka, Zambia
– name: 6 Department of Neurology, University of Rochester, Rochester, New York, United States of America
– name: 1 Blantyre Malaria Project, Queen Elizabeth Central Hospital, Blantyre, Malawi
– name: 3 Department of Osteopathic Medical Specialties, College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan, United States of America
– name: Bach Mai Hospital, VIET NAM
Author_xml – sequence: 1
  givenname: Moses B
  orcidid: 0000-0002-0948-2670
  surname: Chilombe
  fullname: Chilombe, Moses B
  organization: Blantyre Malaria Project, Queen Elizabeth Central Hospital, Blantyre, Malawi
– sequence: 2
  givenname: Michael P
  surname: McDermott
  fullname: McDermott, Michael P
  organization: Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, United States of America
– sequence: 3
  givenname: Karl B
  surname: Seydel
  fullname: Seydel, Karl B
  organization: Department of Osteopathic Medical Specialties, College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan, United States of America
– sequence: 4
  givenname: Manoj
  surname: Mathews
  fullname: Mathews, Manoj
  organization: University Teaching Hospitals Children's Hospital, Lusaka, Zambia
– sequence: 5
  givenname: Musaku
  surname: Mwenechanya
  fullname: Mwenechanya, Musaku
  organization: University Teaching Hospitals Children's Hospital, Lusaka, Zambia
– sequence: 6
  givenname: Gretchen L
  orcidid: 0000-0002-0735-3461
  surname: Birbeck
  fullname: Birbeck, Gretchen L
  organization: Department of Neurology, University of Rochester, Rochester, New York, United States of America
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36206262$$D View this record in MEDLINE/PubMed
BookMark eNqNk89u1DAQxiNURP_AGyCwhITawy5JnDhZDkhV1UKlokot9GpN7EnqyrEX26lYHo5nw2HTahf1gHKINf7N93nGnv1kx1iDSfI6S-cZrbIPd3ZwBvR8GcPzNGd1kRXPkr1sQfMZy1O6s7HeTfa9v0vTktaMvUh2aQyynOV7ye_jrnPovbpHAiao5cphUMITZYhAExxoYtDd28ETv_IBe9KDBqfgI7kOg1yRpbPBCquJbQkQB0baXv1CORM2plutUZIQeU3A-9HJdJtOBNtWCRCrGJRkCQ68CkiExrg0Asd9FMGTw69rX3J2enN6RfxofvQyed6C9vhq-h8k389Ov518mV1cfj4_Ob6YCbbIwwxqUUFV5qxsGymByTxNWZYvUlqxhkHNJKW0bQFLwJYJWBRNU2GDVUNFVjULepC8XesutfV8ar3neZXHxlcFrSNxviakhTu-dKoHt-IWFP8bsK7j4GK9GnnFWIuYlrIWZUGxrNOqBmigkHVZirSKWp8mt6HpUU73sCW6vWPULe_sPV9EvYrRKHA4CTj7Y0AfeK-8QK3BYLzJ8dw0K4t4-Ii--wd9urqJ6iAWoExro68YRflxlWdFVkfXSM2foOInsVfxOWCrYnwr4WgrYXwy-DN0MHjPz6-v_p-9vNlm32-wtwg63Hqrh6Cs8dtgsQaFs947bB-bnKV8HLOHbvBxzPg0ZjHtzeYFPSY9zBX9AyzvKWw
CitedBy_id crossref_primary_10_1371_journal_pone_0294823
crossref_primary_10_1001_jamaneurol_2024_1677
Cites_doi 10.1086/319217
10.1016/S0035-9203(99)90191-8
10.1016/j.cyto.2007.12.008
10.1017/S0012162206000107
10.1186/1475-2875-10-334
10.1186/1475-2875-13-365
10.1038/sj.clpt.6100431
10.1212/WNL.0b013e31826aacd4
10.5492/wjccm.v1.i4.106
10.1097/01.inf.0000114905.87426.c2
10.1515/BC.2003.063
10.4269/ajtmh.14-0216
10.1542/peds.2010-3852
10.1016/j.yebeh.2008.06.008
10.1093/infdis/jis371
10.1016/0140-6736(90)92498-7
10.1038/sj.jp.7211412
10.1007/s12028-011-9588-6
10.1016/S1474-4422(10)70270-2
10.1016/S0035-9203(97)90207-8
10.1016/S1474-4422(05)70247-7
10.1016/S0022-3476(97)70135-5
10.1542/peds.2007-3709
10.1016/0035-9203(92)90420-H
10.1111/j.0013-9580.2004.65103.x
10.1086/314780
10.1093/infdis/jit176
10.1371/journal.pone.0055653
10.1111/j.1365-3156.2006.01685.x
10.1016/S0140-6736(97)02255-1
10.4269/ajtmh.2010.09-0532
10.4269/ajtmh.2000.62.284
10.5001/omj.2010.49
10.1016/0140-6736(91)92295-D
10.1016/S0095-5108(02)00057-X
10.1136/archdischild-2011-300716
10.1002/sim.5525
10.1542/peds.2006-2027
10.1097/00004691-199401000-00002
10.1016/0035-9203(95)90087-X
10.1185/03007990903116255
10.1093/qjmed/89.8.591
10.1086/377583
10.1111/j.1365-3156.2004.01345.x
10.1161/STROKEAHA.107.485508
10.1186/1475-2875-10-148
10.1152/ajpcell.00105.2008
10.1016/S0140-6736(10)61924-1
10.1186/1471-2431-7-30
10.1007/s004360100374
10.1080/02724936.1997.11747899
10.1097/01.ana.0000189079.26212.37
10.1136/adc.2005.087874
10.1038/nrneurol.2012.21
10.1016/0140-6736(91)91907-C
10.1007/s10787-013-0172-x
10.4269/ajtmh.1993.48.216
10.1111/j.1750-3639.2000.tb00251.x
10.1073/pnas.172398999
10.1161/STROKEAHA.108.521583
10.1213/ANE.0b013e3181ce8d34
10.1002/path.1711480406
10.1136/jnnp.2004.043893
10.1345/aph.1M332
ContentType Journal Article
Copyright COPYRIGHT 2022 Public Library of Science
2022 Chilombe et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022 Chilombe et al 2022 Chilombe et al
Copyright_xml – notice: COPYRIGHT 2022 Public Library of Science
– notice: 2022 Chilombe et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022 Chilombe et al 2022 Chilombe et al
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
IOV
ISR
3V.
7QG
7QL
7QO
7RV
7SN
7SS
7T5
7TG
7TM
7U9
7X2
7X7
7XB
88E
8AO
8C1
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABJCF
ABUWG
AFKRA
ARAPS
ATCPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
C1K
CCPQU
D1I
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
KB.
KB0
KL.
L6V
LK8
M0K
M0S
M1P
M7N
M7P
M7S
NAPCQ
P5Z
P62
P64
PATMY
PDBOC
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
PTHSS
PYCSY
RC3
7X8
5PM
DOA
DOI 10.1371/journal.pone.0268414
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Opposing Viewpoints Resource Center
Gale In Context: Science
ProQuest Central (Corporate)
Animal Behavior Abstracts
Bacteriology Abstracts (Microbiology B)
Biotechnology Research Abstracts
ProQuest Nursing & Allied Health Database
Ecology Abstracts
Entomology Abstracts (Full archive)
Immunology Abstracts
Meteorological & Geoastrophysical Abstracts
Nucleic Acids Abstracts
Virology and AIDS Abstracts
Agricultural Science Collection
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
ProQuest Public Health Database
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Materials Science & Engineering Collection
ProQuest Central (Alumni)
ProQuest Central
Advanced Technologies & Aerospace Database‎ (1962 - current)
ProQuest Agricultural & Environmental Science
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Technology Collection
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Materials Science Collection
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Materials Science Database
Nursing & Allied Health Database (Alumni Edition)
Meteorological & Geoastrophysical Abstracts - Academic
ProQuest Engineering Collection
Biological Sciences
Agriculture Science Database
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
ProQuest Engineering Database
Nursing & Allied Health Premium
ProQuest Advanced Technologies & Aerospace Database
ProQuest Advanced Technologies & Aerospace Collection
Biotechnology and BioEngineering Abstracts
Environmental Science Database
Materials Science Collection
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Engineering Collection
Environmental Science Collection
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Agricultural Science Database
Publicly Available Content Database
ProQuest Central Student
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
ProQuest Central China
Environmental Sciences and Pollution Management
Health Research Premium Collection
Meteorological & Geoastrophysical Abstracts
Natural Science Collection
Biological Science Collection
ProQuest Medical Library (Alumni)
Engineering Collection
Advanced Technologies & Aerospace Collection
Engineering Database
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Agricultural Science Collection
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Ecology Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Environmental Science Collection
Entomology Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Environmental Science Database
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
Meteorological & Geoastrophysical Abstracts - Academic
Technology Collection
Technology Research Database
Materials Science Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
Genetics Abstracts
ProQuest Engineering Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Agricultural & Environmental Science Collection
AIDS and Cancer Research Abstracts
Materials Science Database
ProQuest Materials Science Collection
ProQuest Public Health
ProQuest Nursing & Allied Health Source
ProQuest SciTech Collection
Advanced Technologies & Aerospace Database
ProQuest Medical Library
Animal Behavior Abstracts
Materials Science & Engineering Collection
Immunology Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList




CrossRef
MEDLINE - Academic

MEDLINE

Agricultural Science Database
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
Public Health
DocumentTitleAlternate Aggressive antipyretics in central nervous system malaria
EISSN 1932-6203
Editor Luong, Chinh Quoc
Editor_xml – sequence: 1
  givenname: Chinh Quoc
  surname: Luong
  fullname: Luong, Chinh Quoc
ExternalDocumentID 2722687438
oai_doaj_org_article_766fee05d8c543e58078aaba4d855c07
A721418633
10_1371_journal_pone_0268414
36206262
Genre Clinical Trial Protocol
Journal Article
Research Support, N.I.H., Extramural
GeographicLocations Zambia
United States
Malawi
United States--US
GeographicLocations_xml – name: Zambia
– name: United States
– name: Malawi
– name: United States--US
GrantInformation_xml – fundername: NINDS NIH HHS
  grantid: R01 NS102176
– fundername: ;
  grantid: R01NS102176
GroupedDBID ---
123
29O
2WC
3V.
53G
5VS
7RV
7X2
7X7
7XC
88E
8AO
8C1
8CJ
8FE
8FG
8FH
8FI
8FJ
A8Z
AAFWJ
ABDBF
ABIVO
ABJCF
ABUWG
ACGFO
ACIHN
ACIWK
ACPRK
ADBBV
ADRAZ
AEAQA
AENEX
AFKRA
AFRAH
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
APEBS
ARAPS
ATCPS
BAWUL
BBNVY
BBORY
BCNDV
BENPR
BGLVJ
BHPHI
BKEYQ
BPHCQ
BVXVI
BWKFM
CCPQU
CGR
CS3
CUY
CVF
D1I
D1J
D1K
DIK
DU5
E3Z
EAP
EAS
EBD
ECM
EIF
EMOBN
ESTFP
ESX
EX3
F5P
FPL
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
IOV
IPNFZ
IPY
ISE
ISR
ITC
K6-
KB.
KQ8
L6V
LK5
LK8
M0K
M1P
M48
M7P
M7R
M7S
M~E
NAPCQ
NPM
O5R
O5S
OK1
P2P
P62
PATMY
PDBOC
PIMPY
PQQKQ
PROAC
PSQYO
PTHSS
PV9
PYCSY
RIG
RNS
RPM
RZL
SV3
TR2
UKHRP
WOQ
WOW
~02
~KM
AAYXX
AFPKN
CITATION
7QG
7QL
7QO
7SN
7SS
7T5
7TG
7TM
7U9
7XB
8FD
8FK
AZQEC
C1K
DWQXO
FR3
GNUQQ
H94
K9.
KL.
M7N
P64
PQEST
PQUKI
PRINS
RC3
7X8
5PM
AAPBV
ABPTK
BBAFP
N95
ID FETCH-LOGICAL-c692t-a8c7a75265fbdda6d20061290376b6a86d333ffae5aef6ca94bb7ebe7b3c17b93
IEDL.DBID RPM
ISSN 1932-6203
IngestDate Sun Jan 01 07:45:37 EST 2023
Tue Oct 22 14:50:47 EDT 2024
Tue Sep 17 21:31:55 EDT 2024
Sat Oct 26 04:48:14 EDT 2024
Thu Oct 10 18:11:34 EDT 2024
Thu Feb 22 23:39:15 EST 2024
Tue Nov 12 23:08:22 EST 2024
Thu Aug 01 19:24:49 EDT 2024
Thu Aug 01 20:37:24 EDT 2024
Tue Aug 20 21:52:48 EDT 2024
Fri Aug 23 01:59:58 EDT 2024
Sat Nov 02 12:18:55 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Language English
License This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Creative Commons Attribution License
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c692t-a8c7a75265fbdda6d20061290376b6a86d333ffae5aef6ca94bb7ebe7b3c17b93
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
Competing Interests: Birbeck and Seydel receive research funding from the US National Institute of Health. Birbeck serves on the Editorial Board for Lancet Neurology and Neurology. McDermott reports support by a research grants from NIH, FDA, Cure SMA, and PTC Therapeutics; compensation for consulting from Fulcrum Therapeutics, Inc., and NeuroDerm, Ltd.; and service on Data and Safety Monitoring Boards (DSMBs) for Eli Lilly and Company, Catabasis Pharmaceuticals, Inc., Vaccinex, Inc., Neurocrine Biosciences, Inc., Voyager Therapeutics, Prilenia Therapeutics Development, Ltd., ReveraGen BioPharma, Inc., and NS Pharma, Inc. All other authors have nothing to report.
ORCID 0000-0002-0948-2670
0000-0002-0735-3461
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543763/
PMID 36206262
PQID 2722687438
PQPubID 1436336
PageCount e0268414
ParticipantIDs plos_journals_2722687438
doaj_primary_oai_doaj_org_article_766fee05d8c543e58078aaba4d855c07
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9543763
proquest_miscellaneous_2723154226
proquest_journals_2722687438
gale_infotracmisc_A721418633
gale_infotracacademiconefile_A721418633
gale_incontextgauss_ISR_A721418633
gale_incontextgauss_IOV_A721418633
gale_healthsolutions_A721418633
crossref_primary_10_1371_journal_pone_0268414
pubmed_primary_36206262
PublicationCentury 2000
PublicationDate 2022-10-07
PublicationDateYYYYMMDD 2022-10-07
PublicationDate_xml – month: 10
  year: 2022
  text: 2022-10-07
  day: 07
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: San Francisco
– name: San Francisco, CA USA
PublicationTitle PloS one
PublicationTitleAlternate PLoS One
PublicationYear 2022
Publisher Public Library of Science
Public Library of Science (PLoS)
Publisher_xml – name: Public Library of Science
– name: Public Library of Science (PLoS)
References JJ Corry (pone.0268414.ref032) 2012; 1
HM den Hertog (pone.0268414.ref057) 2007; 38
P Bangirana (pone.0268414.ref012) 2006; 11
J Arrich (pone.0268414.ref026) 2010; 110
JA Carter (pone.0268414.ref004) 2005; 76
B Greve (pone.0268414.ref042) 1999; 179
(pone.0268414.ref076) 1994; 11
DG Postels (pone.0268414.ref072) 2014; 91
CH Brandts (pone.0268414.ref049) 1997; 350
GG Graham (pone.0268414.ref058) 2013; 21
R Udomsangpetch (pone.0268414.ref045) 2002; 99
P Bangirana (pone.0268414.ref017) 2011; 10
IM Medana (pone.0268414.ref040) 2003; 188
D Corbett (pone.0268414.ref022) 2000; 10
E Low (pone.0268414.ref028) 2012; 97
B Carme (pone.0268414.ref007) 1993; 48
J Crawley (pone.0268414.ref015) 1996; 89
S Krishna (pone.0268414.ref054) 1995; 89
GL Birbeck (pone.0268414.ref002) 2010; 9
JA Carter (pone.0268414.ref005) 2004; 45
WHO (pone.0268414.ref014) 2010
R Idro (pone.0268414.ref036) 2005; 4
DG Postels (pone.0268414.ref071) 2012; 79
MM Meremikwu (pone.0268414.ref009) 1997; 43
CC John (pone.0268414.ref037) 2008; 41
KB Seydel (pone.0268414.ref052) 2012; 206
JA Carter (pone.0268414.ref018) 2005; 10
GL Birbeck (pone.0268414.ref070) 2010; 82
pone.0268414.ref046
LL Fox (pone.0268414.ref051) 2013; 208
pone.0268414.ref047
AM Dondorp (pone.0268414.ref006) 2011; 376
pone.0268414.ref001
M Magnusson (pone.0268414.ref033) 2008; 84
M. Casteels-Van Daele (pone.0268414.ref062) 1991; 338
OC Nwanyanwu (pone.0268414.ref069) 1999; 93
SM Kariuki (pone.0268414.ref019) 2014; 13
MJ Boivin (pone.0268414.ref013) 2007; 119
H Vinh (pone.0268414.ref064) 2004; 23
AR Laptook (pone.0268414.ref024) 2002; 29
HY Long (pone.0268414.ref048) 2001; 87
HA Choi (pone.0268414.ref031) 2012; 8
M Dobbie (pone.0268414.ref039) 2000; 62
CC John (pone.0268414.ref038) 2008; 122
R Bushra (pone.0268414.ref060) 2010; 25
K Becker (pone.0268414.ref041) 2003; 384
PE Kofoed (pone.0268414.ref055) 2011; 10
JA Carter (pone.0268414.ref003) 2006; 48
ER Southey (pone.0268414.ref068) 2009; 25
Severe and complicated malaria (pone.0268414.ref021) 1990; 84
FS Bondi (pone.0268414.ref008) 1992; 86
IA Clark (pone.0268414.ref043) 1986; 148
Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid H (pone.0268414.ref034) 2011; 15
Section on Clinical P, Therapeutics, Committee on D (pone.0268414.ref067) 2011; 127
NB Agbolosu (pone.0268414.ref056) 1997; 17
ZL Lin (pone.0268414.ref027) 2006; 26
MB van Hensbroek (pone.0268414.ref010) 1997; 131
H Gupta (pone.0268414.ref063) 2007; 44
WHO (pone.0268414.ref074) 2010
DM Greer (pone.0268414.ref023) 2008; 39
SA Karbasi (pone.0268414.ref059) 2010; 86
MD Erlewyn-Lajeunesse (pone.0268414.ref065) 2006; 91
CA Pierce (pone.0268414.ref066) 2010; 44
CR Newton (pone.0268414.ref073) 1997; 91
P Bangirana (pone.0268414.ref016) 2013; 8
P Suz (pone.0268414.ref025) 2006; 18
P Paul (pone.0268414.ref077) 2013; 32
DR Brewster (pone.0268414.ref011) 1990; 336
B Lell (pone.0268414.ref053) 2001; 32
J Crawley (pone.0268414.ref035) 1996; 89
E Chomba (pone.0268414.ref020) 2008; 13
E Smit (pone.0268414.ref030) 2014
(pone.0268414.ref061) 1991; 338
SM Schulzke (pone.0268414.ref029) 2007; 7
MJ Potchen (pone.0268414.ref044) 2012
M Marinkovic (pone.0268414.ref050) 2009; 296
J. Whitehead (pone.0268414.ref075) 1993; 12
References_xml – volume: 32
  start-page: 838
  issue: 5
  year: 2001
  ident: pone.0268414.ref053
  article-title: Effect of antipyretic drugs in children with malaria
  publication-title: Clin Infect Dis
  doi: 10.1086/319217
  contributor:
    fullname: B Lell
– volume: 93
  start-page: 84
  issue: 1
  year: 1999
  ident: pone.0268414.ref069
  article-title: Paracetamol and ibuprofen for treatment of fever in Malawian children aged less than five years
  publication-title: Trans R Soc Trop Med Hyg
  doi: 10.1016/S0035-9203(99)90191-8
  contributor:
    fullname: OC Nwanyanwu
– volume: 41
  start-page: 204
  issue: 3
  year: 2008
  ident: pone.0268414.ref037
  article-title: Elevated serum levels of IL-1ra in children with Plasmodium falciparum malaria are associated with increased severity of disease
  publication-title: Cytokine
  doi: 10.1016/j.cyto.2007.12.008
  contributor:
    fullname: CC John
– volume: 48
  start-page: 51
  issue: 1
  year: 2006
  ident: pone.0268414.ref003
  article-title: Severe falciparum malaria and acquired childhood language disorder
  publication-title: Dev Med Child Neurol
  doi: 10.1017/S0012162206000107
  contributor:
    fullname: JA Carter
– volume: 10
  start-page: 334
  year: 2011
  ident: pone.0268414.ref017
  article-title: Malaria with neurological involvement in Ugandan children: effect on cognitive ability, academic achievement and behaviour
  publication-title: Malaria journal
  doi: 10.1186/1475-2875-10-334
  contributor:
    fullname: P Bangirana
– volume: 13
  start-page: 365
  year: 2014
  ident: pone.0268414.ref019
  article-title: Impairment of executive function in Kenyan children exposed to severe falciparum malaria with neurological involvement
  publication-title: Malaria journal
  doi: 10.1186/1475-2875-13-365
  contributor:
    fullname: SM Kariuki
– volume: 84
  start-page: 52
  issue: 1
  year: 2008
  ident: pone.0268414.ref033
  article-title: Pharmacodynamics of Carbamazepine-mediated Induction of CYP3A4, CYP1A2, and Pgp as Assessed by Probe Substrates Midazolam,Caffeine, and Digoxin
  publication-title: Clinical Pharmacology & Therapeutics
  doi: 10.1038/sj.clpt.6100431
  contributor:
    fullname: M Magnusson
– volume: 79
  start-page: 1268
  issue: 12
  year: 2012
  ident: pone.0268414.ref071
  article-title: Neurologic outcomes in retinopathy-negative cerebral malaria survivors
  publication-title: Neurology
  doi: 10.1212/WNL.0b013e31826aacd4
  contributor:
    fullname: DG Postels
– volume: 1
  start-page: 106
  issue: 4
  year: 2012
  ident: pone.0268414.ref032
  article-title: Use of hypothermia in the intensive care unit
  publication-title: World journal of critical care medicine
  doi: 10.5492/wjccm.v1.i4.106
  contributor:
    fullname: JJ Corry
– volume: 23
  start-page: 226
  issue: 3
  year: 2004
  ident: pone.0268414.ref064
  article-title: Double blind comparison of ibuprofen and paracetamol for adjunctive treatment of uncomplicated typhoid fever
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/01.inf.0000114905.87426.c2
  contributor:
    fullname: H Vinh
– volume: 384
  start-page: 551
  issue: 4
  year: 2003
  ident: pone.0268414.ref041
  article-title: Glutathione—functions and metabolism in the malarial parasite Plasmodium falciparum
  publication-title: Biological chemistry
  doi: 10.1515/BC.2003.063
  contributor:
    fullname: K Becker
– volume: 91
  start-page: 943
  issue: 5
  year: 2014
  ident: pone.0268414.ref072
  article-title: Brain MRI of children with retinopathy-negative cerebral malaria
  publication-title: Am J Trop Med Hyg
  doi: 10.4269/ajtmh.14-0216
  contributor:
    fullname: DG Postels
– volume: 127
  start-page: 580
  issue: 3
  year: 2011
  ident: pone.0268414.ref067
  article-title: Fever and antipyretic use in children
  publication-title: Pediatrics
  doi: 10.1542/peds.2010-3852
  contributor:
    fullname: Section on Clinical P, Therapeutics, Committee on D
– volume: 13
  start-page: 620
  issue: 4
  year: 2008
  ident: pone.0268414.ref020
  article-title: The socioeconomic status of children with epilepsy in Zambia: implications for long-term health and well-being
  publication-title: Epilepsy Behav
  doi: 10.1016/j.yebeh.2008.06.008
  contributor:
    fullname: E Chomba
– volume: 206
  start-page: 309
  issue: 3
  year: 2012
  ident: pone.0268414.ref052
  article-title: Plasma concentrations of parasite histidine-rich protein 2 distinguish between retinopathy-positive and retinopathy-negative cerebral malaria in Malawian children
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jis371
  contributor:
    fullname: KB Seydel
– volume: 336
  start-page: 1039
  issue: 8722
  year: 1990
  ident: pone.0268414.ref011
  article-title: Neurological sequelae of cerebral malaria in children
  publication-title: Lancet
  doi: 10.1016/0140-6736(90)92498-7
  contributor:
    fullname: DR Brewster
– volume: 26
  start-page: 180
  issue: 3
  year: 2006
  ident: pone.0268414.ref027
  article-title: Mild hypothermia via selective head cooling as neuroprotective therapy in term neonates with perinatal asphyxia: an experience from a single neonatal intensive care unit
  publication-title: Journal of perinatology: official journal of the California Perinatal Association
  doi: 10.1038/sj.jp.7211412
  contributor:
    fullname: ZL Lin
– volume: 15
  start-page: 287
  issue: 2
  year: 2011
  ident: pone.0268414.ref034
  article-title: Fever management in SAH
  publication-title: Neurocrit Care
  doi: 10.1007/s12028-011-9588-6
  contributor:
    fullname: Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid H
– volume: 9
  start-page: 1173
  issue: 12
  year: 2010
  ident: pone.0268414.ref002
  article-title: Blantyre Malaria Project Epilepsy Study (BMPES) of neurological outcomes in retinopathy-positive paediatric cerebral malaria survivors: a prospective cohort study
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(10)70270-2
  contributor:
    fullname: GL Birbeck
– volume: 91
  start-page: 161
  issue: 2
  year: 1997
  ident: pone.0268414.ref073
  article-title: Coma scales for children with severe falciparum malaria
  publication-title: Trans R Soc Trop Med Hyg
  doi: 10.1016/S0035-9203(97)90207-8
  contributor:
    fullname: CR Newton
– volume: 4
  start-page: 827
  issue: 12
  year: 2005
  ident: pone.0268414.ref036
  article-title: Pathogenesis, clinical features, and neurological outcome of cerebral malaria
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(05)70247-7
  contributor:
    fullname: R Idro
– volume: 86
  start-page: 228
  issue: 3
  year: 2010
  ident: pone.0268414.ref059
  article-title: Comparison of antipyretic effectiveness of equal doses of rectal and oral acetaminophen in children
  publication-title: Jornal de pediatria
  contributor:
    fullname: SA Karbasi
– volume: 131
  start-page: 125
  issue: 1
  year: 1997
  ident: pone.0268414.ref010
  article-title: Residual neurologic sequelae after childhood cerebral malaria
  publication-title: J Pediatr
  doi: 10.1016/S0022-3476(97)70135-5
  contributor:
    fullname: MB van Hensbroek
– volume: 122
  start-page: e92
  issue: 1
  year: 2008
  ident: pone.0268414.ref038
  article-title: Cerebral malaria in children is associated with long-term cognitive impairment
  publication-title: Pediatrics
  doi: 10.1542/peds.2007-3709
  contributor:
    fullname: CC John
– volume: 86
  start-page: 17
  issue: 1
  year: 1992
  ident: pone.0268414.ref008
  article-title: The incidence and outcome of neurological abnormalities in childhood cerebral malaria: a long-term follow-up of 62 survivors
  publication-title: Trans R Soc Trop Med Hyg
  doi: 10.1016/0035-9203(92)90420-H
  contributor:
    fullname: FS Bondi
– year: 2012
  ident: pone.0268414.ref044
  article-title: Acute Brain MRI Findings in 120 Malawian Children with Cerebral Malaria: New Insights into an Ancient Disease
  publication-title: AJNR Am J Neuroradiol
  contributor:
    fullname: MJ Potchen
– volume: 45
  start-page: 978
  issue: 8
  year: 2004
  ident: pone.0268414.ref005
  article-title: Increased prevalence of epilepsy associated with severe falciparum malaria in children
  publication-title: Epilepsia
  doi: 10.1111/j.0013-9580.2004.65103.x
  contributor:
    fullname: JA Carter
– volume: 84
  start-page: 1
  issue: Suppl 2
  year: 1990
  ident: pone.0268414.ref021
  article-title: World Health Organization, Division of Control of Tropical Diseases
  publication-title: Trans R Soc Trop Med Hyg
  contributor:
    fullname: Severe and complicated malaria
– volume: 179
  start-page: 1584
  issue: 6
  year: 1999
  ident: pone.0268414.ref042
  article-title: High oxygen radical production is associated with fast parasite clearance in children with Plasmodium falciparum malaria
  publication-title: J Infect Dis
  doi: 10.1086/314780
  contributor:
    fullname: B Greve
– volume: 208
  start-page: 500
  issue: 3
  year: 2013
  ident: pone.0268414.ref051
  article-title: Histidine-rich protein 2 plasma levels predict progression to cerebral malaria in Malawian children with Plasmodium falciparum infection
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jit176
  contributor:
    fullname: LL Fox
– ident: pone.0268414.ref046
– volume: 8
  start-page: e55653
  issue: 2
  year: 2013
  ident: pone.0268414.ref016
  article-title: The association between cognition and academic performance in Ugandan children surviving malaria with neurological involvement
  publication-title: PloS one
  doi: 10.1371/journal.pone.0055653
  contributor:
    fullname: P Bangirana
– volume: 11
  start-page: 1341
  issue: 9
  year: 2006
  ident: pone.0268414.ref012
  article-title: Rehabilitation for cognitive impairments after cerebral malaria in African children: strategies and limitations
  publication-title: Trop Med Int Health
  doi: 10.1111/j.1365-3156.2006.01685.x
  contributor:
    fullname: P Bangirana
– volume: 350
  start-page: 704
  issue: 9079
  year: 1997
  ident: pone.0268414.ref049
  article-title: Effect of paracetamol on parasite clearance time in Plasmodium falciparum malaria
  publication-title: Lancet
  doi: 10.1016/S0140-6736(97)02255-1
  contributor:
    fullname: CH Brandts
– volume: 82
  start-page: 231
  issue: 2
  year: 2010
  ident: pone.0268414.ref070
  article-title: Identification of malaria retinopathy improves the specificity of the clinical diagnosis of cerebral malaria: findings from a prospective cohort study
  publication-title: Am J Trop Med Hyg
  doi: 10.4269/ajtmh.2010.09-0532
  contributor:
    fullname: GL Birbeck
– volume: 62
  start-page: 284
  issue: 2
  year: 2000
  ident: pone.0268414.ref039
  article-title: Cerebrospinal fluid studies in children with cerebral malaria: an excitotoxic mechanism?
  publication-title: Am J Trop Med Hyg
  doi: 10.4269/ajtmh.2000.62.284
  contributor:
    fullname: M Dobbie
– volume: 25
  start-page: 155
  issue: 3
  year: 2010
  ident: pone.0268414.ref060
  article-title: An Overview of Clinical Pharmacology of Ibuprofen
  publication-title: Oman Medical Journal
  doi: 10.5001/omj.2010.49
  contributor:
    fullname: R Bushra
– volume: 338
  start-page: 1408
  issue: 8779
  year: 1991
  ident: pone.0268414.ref062
  article-title: Management of childhood fever
  publication-title: Lancet
  doi: 10.1016/0140-6736(91)92295-D
  contributor:
    fullname: M. Casteels-Van Daele
– volume: 29
  start-page: 623
  issue: 4
  year: 2002
  ident: pone.0268414.ref024
  article-title: The effects of temperature on hypoxic-ischemic brain injury
  publication-title: Clin Perinatol
  doi: 10.1016/S0095-5108(02)00057-X
  contributor:
    fullname: AR Laptook
– volume: 97
  start-page: F267
  issue: 4
  year: 2012
  ident: pone.0268414.ref028
  article-title: Cooling and seizure burden in term neonates: an observational study
  publication-title: Arch Dis Child Fetal Neonatal Ed
  doi: 10.1136/archdischild-2011-300716
  contributor:
    fullname: E Low
– volume: 32
  start-page: 67
  issue: 1
  year: 2013
  ident: pone.0268414.ref077
  article-title: Standardizing the power of the Hosmer-Lemeshow goodness of fit test in large data sets
  publication-title: Stat Med
  doi: 10.1002/sim.5525
  contributor:
    fullname: P Paul
– volume: 119
  start-page: e360
  issue: 2
  year: 2007
  ident: pone.0268414.ref013
  article-title: Cognitive impairment after cerebral malaria in children: a prospective study
  publication-title: Pediatrics
  doi: 10.1542/peds.2006-2027
  contributor:
    fullname: MJ Boivin
– volume: 11
  start-page: 2
  issue: 1
  year: 1994
  ident: pone.0268414.ref076
  article-title: Guideline one: minimum technical requirements for performing clinical electroencephalography. American Electroencephalographic Society
  publication-title: J Clin Neurophysiol
  doi: 10.1097/00004691-199401000-00002
– volume: 12
  start-page: 2257
  year: 1993
  ident: pone.0268414.ref075
  publication-title: Sample size calculations for ordered categorical data Statist Med
  contributor:
    fullname: J. Whitehead
– volume: 43
  start-page: 231
  issue: 8
  year: 1997
  ident: pone.0268414.ref009
  article-title: The pattern of neurological sequelae of childhood cerebral malaria among survivors in Calabar, Nigeria
  publication-title: Cent Afr J Med
  contributor:
    fullname: MM Meremikwu
– volume: 89
  start-page: 507
  issue: 5
  year: 1995
  ident: pone.0268414.ref054
  article-title: Fever in uncomplicated Plasmodium falciparum malaria: randomized double- ’blind’ comparison of ibuprofen and paracetamol treatment
  publication-title: Trans R Soc Trop Med Hyg
  doi: 10.1016/0035-9203(95)90087-X
  contributor:
    fullname: S Krishna
– volume: 25
  start-page: 2207
  issue: 9
  year: 2009
  ident: pone.0268414.ref068
  article-title: Systematic review and meta-analysis of the clinical safety and tolerability of ibuprofen compared with paracetamol in paediatric pain and fever
  publication-title: Current medical research and opinion
  doi: 10.1185/03007990903116255
  contributor:
    fullname: ER Southey
– volume: 89
  start-page: 591
  issue: 8
  year: 1996
  ident: pone.0268414.ref035
  article-title: Seizures and status epilepticus in childhood cerebral malaria
  publication-title: Qjm
  doi: 10.1093/qjmed/89.8.591
  contributor:
    fullname: J Crawley
– volume: 89
  start-page: 591
  issue: 8
  year: 1996
  ident: pone.0268414.ref015
  article-title: Seizures and status epilepticus in childhood cerebral malaria
  publication-title: QJM
  doi: 10.1093/qjmed/89.8.591
  contributor:
    fullname: J Crawley
– volume: 188
  start-page: 844
  issue: 6
  year: 2003
  ident: pone.0268414.ref040
  article-title: Metabolites of the kynurenine pathway of tryptophan metabolism in the cerebrospinal fluid of Malawian children with malaria
  publication-title: J Infect Dis
  doi: 10.1086/377583
  contributor:
    fullname: IM Medana
– volume: 10
  start-page: 3
  issue: 1
  year: 2005
  ident: pone.0268414.ref018
  article-title: Developmental impairments following severe falciparum malaria in children
  publication-title: Trop Med Int Health
  doi: 10.1111/j.1365-3156.2004.01345.x
  contributor:
    fullname: JA Carter
– ident: pone.0268414.ref001
– volume: 38
  start-page: e131
  issue: 11
  year: 2007
  ident: pone.0268414.ref057
  article-title: Acetaminophen for temperature reduction in acute stroke: potential but unproven benefits
  publication-title: Stroke
  doi: 10.1161/STROKEAHA.107.485508
  contributor:
    fullname: HM den Hertog
– ident: pone.0268414.ref047
– volume: 10
  start-page: 148
  year: 2011
  ident: pone.0268414.ref055
  article-title: Paracetamol versus placebo in treatment of non-severe malaria in children in Guinea-Bissau: a randomized controlled trial
  publication-title: Malaria journal
  doi: 10.1186/1475-2875-10-148
  contributor:
    fullname: PE Kofoed
– volume: 296
  start-page: C59
  issue: 1
  year: 2009
  ident: pone.0268414.ref050
  article-title: Febrile temperature leads to significant stiffening of Plasmodium falciparum parasitized erythrocytes
  publication-title: American journal of physiology Cell physiology
  doi: 10.1152/ajpcell.00105.2008
  contributor:
    fullname: M Marinkovic
– volume: 376
  start-page: 1647
  issue: 9753
  year: 2011
  ident: pone.0268414.ref006
  article-title: Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)61924-1
  contributor:
    fullname: AM Dondorp
– volume: 7
  start-page: 30
  year: 2007
  ident: pone.0268414.ref029
  article-title: A systematic review of cooling for neuroprotection in neonates with hypoxic ischemic encephalopathy—are we there yet?
  publication-title: BMC pediatrics
  doi: 10.1186/1471-2431-7-30
  contributor:
    fullname: SM Schulzke
– volume: 87
  start-page: 553
  issue: 7
  year: 2001
  ident: pone.0268414.ref048
  article-title: Plasmodium falciparum: in vitro growth inhibition by febrile temperatures
  publication-title: Parasitology research
  doi: 10.1007/s004360100374
  contributor:
    fullname: HY Long
– volume: 17
  start-page: 283
  issue: 3
  year: 1997
  ident: pone.0268414.ref056
  article-title: Efficacy of tepid sponging versus paracetamol in reducing temperature in febrile children
  publication-title: Ann Trop Paediatr
  doi: 10.1080/02724936.1997.11747899
  contributor:
    fullname: NB Agbolosu
– volume: 18
  start-page: 5
  issue: 1
  year: 2006
  ident: pone.0268414.ref025
  article-title: Clinical features of fever associated with poor outcome in severe pediatric traumatic brain injury
  publication-title: Journal of neurosurgical anesthesiology
  doi: 10.1097/01.ana.0000189079.26212.37
  contributor:
    fullname: P Suz
– volume: 91
  start-page: 414
  issue: 5
  year: 2006
  ident: pone.0268414.ref065
  article-title: Randomised controlled trial of combined paracetamol and ibuprofen for fever
  publication-title: Arch Dis Child
  doi: 10.1136/adc.2005.087874
  contributor:
    fullname: MD Erlewyn-Lajeunesse
– volume: 8
  start-page: 214
  issue: 4
  year: 2012
  ident: pone.0268414.ref031
  article-title: Hypothermia for acute brain injury—mechanisms and practical aspects
  publication-title: Nature reviews Neurology
  doi: 10.1038/nrneurol.2012.21
  contributor:
    fullname: HA Choi
– volume: 338
  start-page: 1049
  issue: 8774
  year: 1991
  ident: pone.0268414.ref061
  article-title: Management of childhood fever
  publication-title: Lancet
  doi: 10.1016/0140-6736(91)91907-C
– volume: 21
  start-page: 201
  issue: 3
  year: 2013
  ident: pone.0268414.ref058
  article-title: The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings
  publication-title: Inflammopharmacology
  doi: 10.1007/s10787-013-0172-x
  contributor:
    fullname: GG Graham
– volume: 48
  start-page: 216
  issue: 2
  year: 1993
  ident: pone.0268414.ref007
  article-title: Mortality and sequelae due to cerebral malaria in African children in Brazzaville, Congo
  publication-title: Am J Trop Med Hyg
  doi: 10.4269/ajtmh.1993.48.216
  contributor:
    fullname: B Carme
– volume: 10
  start-page: 145
  issue: 1
  year: 2000
  ident: pone.0268414.ref022
  article-title: Temperature modulation (hypothermic and hyperthermic conditions) and its influence on histological and behavioral outcomes following cerebral ischemia
  publication-title: Brain Pathol
  doi: 10.1111/j.1750-3639.2000.tb00251.x
  contributor:
    fullname: D Corbett
– volume: 44
  start-page: 903
  issue: 12
  year: 2007
  ident: pone.0268414.ref063
  article-title: Role of paracetamol in treatment of childhood Fever: a double-blind randomized placebo controlled trial
  publication-title: Indian Pediatr
  contributor:
    fullname: H Gupta
– year: 2014
  ident: pone.0268414.ref030
  article-title: Cooling neonates who do not fulfil the standard cooling criteria—short and long term outcomes
  publication-title: Acta paediatrica
  contributor:
    fullname: E Smit
– volume: 99
  start-page: 11825
  issue: 18
  year: 2002
  ident: pone.0268414.ref045
  article-title: Febrile temperatures induce cytoadherence of ring-stage Plasmodium falciparum-infected erythrocytes
  publication-title: Proceedings of the National Academy of Sciences of the United States of America
  doi: 10.1073/pnas.172398999
  contributor:
    fullname: R Udomsangpetch
– start-page: 194
  volume-title: Guidelines for the Treatment of Malaria
  year: 2010
  ident: pone.0268414.ref074
  contributor:
    fullname: WHO
– volume: 39
  start-page: 3029
  issue: 11
  year: 2008
  ident: pone.0268414.ref023
  article-title: Impact of fever on outcome in patients with stroke and neurologic injury: a comprehensive meta-analysis
  publication-title: Stroke
  doi: 10.1161/STROKEAHA.108.521583
  contributor:
    fullname: DM Greer
– volume: 110
  start-page: 1239
  issue: 4
  year: 2010
  ident: pone.0268414.ref026
  article-title: Cochrane corner: hypothermia for neuroprotection in adults after cardiopulmonary resuscitation
  publication-title: Anesthesia and analgesia
  doi: 10.1213/ANE.0b013e3181ce8d34
  contributor:
    fullname: J Arrich
– volume: 148
  start-page: 301
  issue: 4
  year: 1986
  ident: pone.0268414.ref043
  article-title: Injection of free radical generators causes premature onset of tissue damage in malaria-infected mice
  publication-title: The Journal of pathology
  doi: 10.1002/path.1711480406
  contributor:
    fullname: IA Clark
– volume: 76
  start-page: 476
  issue: 4
  year: 2005
  ident: pone.0268414.ref004
  article-title: Persistent neurocognitive impairments associated with severe falciparum malaria in Kenyan children
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp.2004.043893
  contributor:
    fullname: JA Carter
– volume-title: WHO. Guidelines for the treatment of malaria
  year: 2010
  ident: pone.0268414.ref014
  contributor:
    fullname: WHO
– volume: 44
  start-page: 489
  issue: 3
  year: 2010
  ident: pone.0268414.ref066
  article-title: Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review
  publication-title: The Annals of pharmacotherapy
  doi: 10.1345/aph.1M332
  contributor:
    fullname: CA Pierce
SSID ssj0053866
Score 2.4677308
Snippet Malaria remains a major public health challenge in Africa where annually, ~250,000 children with malaria experience a neurologic injury with subsequent...
Background Malaria remains a major public health challenge in Africa where annually, ~250,000 children with malaria experience a neurologic injury with...
Background Malaria remains a major public health challenge in Africa where annually, ~250,000 children with malaria experience a neurologic injury with...
BackgroundMalaria remains a major public health challenge in Africa where annually, ~250,000 children with malaria experience a neurologic injury with...
SourceID plos
doaj
pubmedcentral
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage e0268414
SubjectTerms Acetaminophen
Acetaminophen - therapeutic use
Analgesics
Animals
Antipyretics
Antipyretics - therapeutic use
Biology and Life Sciences
Brain injury
Causes of
Central Nervous System
Central nervous system diseases
Child
Children
Clinical trials
Coma
Complications and side effects
Convulsions & seizures
Drug therapy
Effectiveness
Epilepsy
Evaluation
Fever
Fever - drug therapy
Fever - prevention & control
Head injuries
Health risks
Health services
Histidine
Humans
Hyperthermia
Ibuprofen
Ibuprofen - therapeutic use
Informed consent
Malaria
Malaria, Falciparum - complications
Malaria, Falciparum - drug therapy
Maximum temperatures
Medicine and Health Sciences
Neurological complications
Neuroprotection
Neuroprotective Agents - therapeutic use
Nonsteroidal anti-inflammatory drugs
Parasites
Pediatrics
People and Places
Peripheral blood
Proteins
Public health
Randomization
Randomized Controlled Trials as Topic
Reduction
Risk analysis
Risk factors
Seizures
Seizures - drug therapy
Study Protocol
Temperature effects
Testing
Therapy
Traumatic brain injury
Treatment Outcome
Vector-borne diseases
Zambia
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF6hnrggyquGAgNCoj24tb32rs0toEQFqSAVWvVm7cttpNaJcIoUfhy_jZn1JopRJThws7xjO5n5dnZGO_MtY2-UK4RNMhNXTWLjvMArpXUWW26NTquqafyhfcefxdFp_um8ON846otqwnp64F5xh1KIxrmksKUpcu4K4kdXSqvclkVhQh95Uq2Sqd4H4ywWIjTKcZkeBrsczGetO0iI4CTNBwuR5-tfe-Wt-dWsuy3k_LNycmMpmtxn90IMCaP-t2-zO659wLbDLO1gL1BJ7z9kv0YXPp9Glwaowul86ZsWO5i2EF4OKPsD03_oOZ3hWmGuO1XvgCoMl0A8DjMEC8waUIALm51dT386G4ca9ytnwZ_8AcpvH-NKuPklcERRocwSb1ognnHarQZDh1UQ3iDUk8Decf9dmIzPxifgWW_3H7HTyfjbh6M4nNgQG1Fli1iVRipJjPuNtlYJm_kQqkrQjWmhSmE5502DAFGuEUZVudYSYSQ1N6nUFX_Mtlq00Q4DlaLnLUWuTZnnWZYqadNSYXxmeWMLXUQsXpmvnvfEHLXfnZOY0PR2qMncdTB3xN6TjdeyRKvtbyDY6gC2-m9gi9hLQkjd96iunUM9wjw6T0vBecReewmi1mipdudC3XRd_fHL2T8IfT0ZCL0NQs0M4YCm6vsl8D8RZddAcncgiQ7CDIZ3CM8rrXR1JjHmLjF0LPHJFcZvH361HqaXUj1e6xCSJMMx-EbBiD3pp8RasxgSJZgmZxGTg8kyUP1wpJ1eembzCrWOC97T_2GrZ-xuRq0qVOwhd9nW4vuNe44B5EK_8L7iN4KadLE
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELegvCAhxMbHAgMMQmJ7yJbEiZ3wggpqNZAG0mBT3yJ_pVTakrK0SOWP42_jznHLgibEWxVf6_TufL6z735HyCtpM26iRIdFFZkwzeCTVCoJDTNaxUVRVa5p3_EnfnSafpxkE3_g1vq0yrVNdIbaNBrPyA8TAY5CDvtd_nb-PcSuUXi76lto3CS34iTimNIlJpuAC9Yy575cjon40EvnYN7U9iBCmJM47W1HDrV_Y5sH8_Omvc7x_Dt_8sqGNL5H7npPkg470W-RG7beJne6YzjaVRdtky2_dlu65wGm9--TX8Opi7LB0FFg7Gy-cqWMLZ3V1E9GgfZHs2xph_RMLyREwDP5hmLe4YoiukMDKkSbikoK251pLmY_rQl95vu5NdT1A6HSXSrD_nh1JmoRuELqFTw0FNHHkctUYwsL1ELqs0zo3nE3Lx2PzkYn1GHh7j8gp-PR1_dHoe_jEGpeJItQ5lpIgTj8lTJGcpM4x6qIwLgpLnNuGGNVBWojbcW1LFKlBCiXUEzHQhXsIRnUILMdQmUM9jjnqdJ5miZJLIWJcwlem2GVyVQWkHAtznLewXWU7s5OQJjTyaVE8Zde_AF5hzLf0CLYtnvQXE5Lv3ZLwXllbZSZXGcpsxlC9EupZGryLNORCMhz1Jiyq1zdmIxyCNF1GuecsYC8dBQIuFFjRs9ULtu2_PD57D-Ivpz0iF57oqoBdQBRdVUU8J8QyKtHudujBLOhe8M7qN9rrrTlnwUG31zr_PXDLzbD-KOYpVdbUEmkYeCSA2FAHnVLZMNZcJQiCJ6TgIje4umxvj9Sz745vPMCuA7b4ON_v9YTcjvB0hRM7hC7ZLC4XNqn4DAu1DNnFX4DeLlxAg
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3daxNBEF9KfBFEbP3oadVVBNuHC_e5eyeIREmoQhWqKX079utiIL2LuUSMf5x_mzN7m9CTFHwLt7PZy8zs7Ex25jeEvBImZTqIlJ-XgfaTFD4JKSNfx1rJMM_L0jbtO_vMTsfJp8v0co9serY6BjY7QzvsJzVezPq_fqzfwYZ_a7s28HAzqT-vK9MPEL4EO1vfihKI1TGZL9neK8DuZswV0N00s3NAWRz_rbXuzWd1s8sV_Tej8toRNbpH7jrfkg5aZdgne6Y6IHfaP-ZoW290QPbdbm7osYOcPrlP_gwmNu4G00eB1dP52hY3NnRaUbcYBdqf9aqhLfYzvRLAuKl4QzETcU0R76EGpaJ1SQWFA1DXV9PfRvsuF35mNLUdQqiw18xwYl5fiRqEshBqDQ81RTxyvNWmCptaoF5Sl3dCj8_adeloeDE8pxYd9-QBGY-G3z6c-q6zg69YHi19kSkuOCLzl1JrwXRkXa08AHMnmciYjuO4LEGRhCmZEnkiJQd14zJWIZd5_JD0KpDZIaEiBAudsUSqLEmiKBRch5kAP07HpU5l6hF_I85i3gJ4FPYWj0Pg08qlQPEXTvweeY8y39Ii_LZ9UC8mhdvNBWesNCZIdabSJDYpgvYLIUWiszRVAffIc9SYoq1l3RqRYgDxdhJmLI498tJSIARHhTk-E7FqmuLjl4v_IPp63iF67YjKGtQBRNXWVcBvQmivDuVRhxIMieoMH6J-b7jSFBEH3zwDFzODmRud3z38YjuMX4p5e5UBlUSaGJx0IPTIo3aLbDkLrlMA4XTkEd7ZPB3Wd0eq6XeLgJ4D1-FgfHzzGz8htyMsVMFUD35EesvFyjwF93Epn1mL8BelWnUG
  priority: 102
  providerName: Scholars Portal
Title Aggressive antipyretics in central nervous system malaria: Study protocol of a randomized-controlled trial assessing antipyretic efficacy and parasite clearance effects (Malaria FEVER study)
URI https://www.ncbi.nlm.nih.gov/pubmed/36206262
https://www.proquest.com/docview/2722687438
https://www.proquest.com/docview/2723154226
https://pubmed.ncbi.nlm.nih.gov/PMC9543763
https://doaj.org/article/766fee05d8c543e58078aaba4d855c07
http://dx.doi.org/10.1371/journal.pone.0268414
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF615cIFUV4NlLAgJNqDEz93bW5plFCQUqpAq96sfdhppMaO6gQpHPhp_DZm1uuoRj0gLqvIO7aTnW9mZ7Mz3xLyXmQR066vnCR3tRNG8ElI6Ts60Ep6SZLn5tC-yRk7vQi_XEVXOyRqamFM0r6S815xs-gV82uTW7lcqH6TJ9Y_nwyTKES76O-SXQBos0Sv3S8YMGO2Ri7gXt-qpLcsi6znIreJh2fxgN92IZb3W9ORYe3f-ua95U1Z3Rd4_p0_eWdCGj8mj2wkSQf1N94nO1nxhOxbW63okSWUPn5Kfg9mZlUNjo3CQM6XG1O6WNF5Qe3DKcj-KNcVrZmd6ULAincuPlLMM9xQZHMoATK0zKmgML3pcjH_mWnHZrrfZJqa8z-oMJvIMB_efRPNkKhCqA1c1BTZxnHPmio8sgJRR21WCT2a1O-l49HlaEoN9-3xM3IxHn0fnjr23AZHscRfOSJWXHDk3c-l1oJp3wRSiQtKk0zETAdBkOcAE5HlTIkklJIDmLgMlMdlEjwnewWo64BQ4YH_jVkoVRyGvu8Jrr1YQJSmg1xHMuoQp1FfuqzpOVKzR8dhWVPrIUXNp1bzHXKCOt7KIrm2uVDezlILsZQzlmeZG-lYAdCyCCn5hZAi1HEUKZd3yBtESFpXqm5dRDqA1XToxSwIOuSdkUCCjQIzeGZiXVXp56-X_yD0bdoS-mCF8hLgAKqqqybgNyFxV0vysCUJbkK1ug8Qz82oVKnPIfKOIYCM4c4G4_d3v91240MxK6_IAJIoE0AIDoId8qI2ie3INgbWIbxlLK2hb_eAuRt-c2veL__7zlfkoY9VKpjnwQ_J3up2nb2G2HElu-Axrji08dDDdvypSx6cjM7Op13zbwy0kzDG9teoa_zKH0znfC0
link.rule.ids 230,315,730,783,787,867,888,2109,2228,12068,12235,12777,21400,24330,27936,27937,31731,31732,33278,33279,33385,33386,33756,33757,43322,43591,43612,43817,53804,53806,74073,74342,74363,74630
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELegPICEEBsfCwxmEBLbQ7Z82gkvqKBWHaxDGtvUt8gfSam0JWVpkcofx9_GneOGBU2Ityq-1und-Xxn3_2OkDcij5n2AuWmhafdKIZPQsrA1aFW0k_TojBN-8bHbHQWfZrEE3vgVtu0yrVNNIZaVwrPyA8CDo5CAvtd8n7-3cWuUXi7alto3CZ3EIcLOxjwSRtwwVpmzJbLhdw_sNLZn1dlvu8hzIkfdbYjg9rf2ube_KKqb3I8_86fvLYhDR-SB9aTpP1G9BvkVl5ukvvNMRxtqos2yYZduzXdtQDTe4_Ir_7URNlg6CgwdjZfmVLGms5KaiejQPujWta0QXqmlwIi4Jl4RzHvcEUR3aECFaJVQQWF7U5Xl7OfuXZt5vtFrqnpB0KFuVSG_fH6TDRH4AqhVvBQU0QfRy5ThS0sUAupzTKhu-NmXjocnA9OqMHC3XtMzoaD048j1_ZxcBVLg4UrEsUFRxz-QmotmA6MY5V6YNwkEwnTYRgWBaiNyAumRBpJyUG5uAyVz2UaPiG9EmS2RajwwR4nLJIqiaIg8AXXfiLAa9NhoWMZO8RdizObN3Admbmz4xDmNHLJUPyZFb9DPqDMW1oE2zYPqqtpZtduxhkr8tyLdaLiKMxjhOgXQopIJ3GsPO6QHdSYrKlcbU1G1ofoOvITFoYOeW0oEHCjxIyeqVjWdXb45fw_iL6edIjeWqKiAnUAUTVVFPCfEMirQ7ndoQSzoTrDW6jfa67U2Z8FBt9c6_zNw6_aYfxRzNIrc1BJpAnBJQdChzxtlkjLWXCUPAieA4fwzuLpsL47Us6-GbzzFLgO2-Czf7_WDrk7Oh0fZUeHx5-fk3sBlqlgogffJr3F1TJ_Ac7jQr40FuI32qRz6Q
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELegSAgJITY-FhjMICS2h6xJnNgJL6iMVhuwgcY27S3yR1IqbUlZVqTyx_G3cee4ZUET4q2Kr016347vfkfIK1kk3ASR9rMyMH6cwCepVOQbZrQKs6ws7dC-_QO-exx_OE1OXf1T48oqFz7ROmpTa3xH3o8EJAopxLu0X7qyiC_vR2-n332cIIUnrW6cxk1yC6hinGaQ7izLPcCuOXetc0yEfSep7WldFdsBQp6EcSc0WQT_pZ_uTc_q5rok9O9ayivBaXSf3HNZJR20arBCbhTVKrnbvpKjbafRKllxdtzQTQc2vfWA_BqM7Y4bnB4FJk-mc9vW2NBJRd3NKND-qGcNbVGf6bmE3fBEvqFYgziniPRQgzrRuqSSQugz9fnkZ2F8VwV_VhhqZ4NQaQ-YIVZevRMtEMRC6jlcNBSRyJHLVOM4C9RI6ipO6OZ-e186Gp4MD6nFxd16SI5Hw6OdXd_NdPA1z6JLX6ZaSIGY_KUyRnIT2SQrC8DRKS5TbhhjZQkqJIuSa5nFSglQNKGYDoXK2CPSq0Bma4TKEHxzymOl0ziOolAKE6YSMjjDSpOoxCP-Qpz5tIXuyO35nYAtTyuXHMWfO_F75B3KfEmLwNv2Qn0xzp0d54LzsiiCxKQ6iVmRIFy_lErGJk0SHQiPbKDG5G0X69J95APYacdhyhnzyEtLgeAbFarxWM6aJt_7fPIfRF8PO0SvHVFZgzqAqNqOCvhPCOrVoVzvUIIL0Z3lNdTvBVea_I-xwTcXOn_98ovlMv4oVuxVBagk0jBIz4HQI49bE1lyFpKmADbSkUdEx3g6rO-uVJNvFvs8A65DSHzy78faILfBOeSf9g4-PiV3IuxYwZoPsU56lxez4hnkkZfquXUQvwHhl3fs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Aggressive+antipyretics+in+central+nervous+system+malaria%3A+Study+protocol+of+a+randomized-controlled+trial+assessing+antipyretic+efficacy+and+parasite+clearance+effects+%28Malaria+FEVER+study%29&rft.jtitle=PloS+one&rft.au=Chilombe%2C+Moses&rft.au=McDermott%2C+Michael&rft.au=Seydel%2C+Karl&rft.au=Mathews%2C+Manoj&rft.date=2022-10-07&rft.pub=Public+Library+of+Science&rft.eissn=1932-6203&rft.volume=17&rft.issue=10&rft_id=info:doi/10.1371%2Fjournal.pone.0268414&rft.externalDocID=2722687438
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon